HOME >> MEDICINE >> NEWS
Pathway may provide target for treating chronic pain

of how and why they become active.

In Nature last year, Zhuo and colleague Ping Li, M.D., a research associate in anesthesiology, reported that they could identify silent synapses by monitoring electrical responses of individual neurons. After these synapses were awakened, they remained active and able to relay painful sensory information to the brain even after the painful stimulus was gone.

In those experiments, the researchers showed that the silent synapses could be activated both by strong pain signals and by messages from a brain region called the rostroventral medulla (RVM), which sends chemical signals to the dorsal horn of the spinal cord. But little was known about what happens inside a nerve cell when a silent synapse is activated.

In the current study, Zhuo and colleagues found that activation of silent synapses involves an interaction between AMPA receptors and a protein called glutamate receptor interacting protein (GRIP).

"One hypothesis is that GRIP binds to the cell at an AMPA receptor site inside of the cell," Zhuo said. "Then, under certain conditions, the receptor moves itself to the synaptic part of the neuron. That movement activates the formerly silent synapse."

Receptors at synapses receive messages from other neurons. AMPA receptors are sensitive to a brain chemical called glutamate.

"AMPA receptors are highly dynamic," said co-investigator Morgan Sheng, M.D., Ph.D., associate professor of neurobiology at Massachusetts General Hospital and Harvard Medical School and assistant investigator with the Howard Hughes Medical Institute. "They can be recruited to and removed from the synapse. It's actually a marvelously simple way to regulate synaptic strength. You silence a synapse by taking away receptors and strengthen it by adding more receptors."

Zhuo compares the process to an overnight courier service. Each evening, many packages come in. But the next morning, those packages go back out, allowing the office to m
'"/>

Contact: Jim Dryden
dryden@medicine.wustl.edu
314-286-0110
Washington University School of Medicine
17-Oct-1999


Page: 1 2 3

Related medicine news :

1. Cell Pathways Aptosyn™ (exisulind) shows continuing long-term prevention of colon polyps in FAP patients
2. Study provides new estimates of the causes of child mortality worldwide
3. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
4. End AIDS drug waiting lists, HIV care providers tell policymakers
5. Artery clearing system does not provide benefit for patients undergoing PCI
6. Newly identified gene cluster on mouse X chromosome provides insights into fertility
7. University of Washington joins new Autism Treatment Network to provide better medical services
8. Rat whisking may provide insight into debilitating eye disorder
9. Researchers hope monkeys can provide new insights into depression
10. AGI and USGS provide unique tsunami disaster relief
11. New ITN Scholars Program provides junior faculty opportunity to develop clinical trials expertise

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pathway may provide target for treating chronic pain

(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: